ethnopharmacolog
relev
yu
ping
feng
san
ypf
chines
jade
windscreen
powder
wellknown
tradit
chines
medicin
commonli
use
cure
diseas
respiratori
system
immun
system
aim
studi
select
sensit
highperform
liquid
chromatographi
coupl
mass
spectrometri
method
hplcm
develop
valid
simultan
quantif
cycloastragenol
formononetin
calycosin
gmv
cimifugin
rat
plasma
oral
administr
yu
ping
feng
san
decoct
materi
method
plasma
sampl
extract
via
solidphas
extract
spe
separ
zorbax
column
detect
singl
quadrupl
mass
spectrometri
electrospray
ioniz
interfac
quantifi
use
select
ion
monitor
mode
current
spehplcm
assay
valid
linear
intraday
interday
precis
accuraci
extract
recoveri
stabil
method
appli
compar
pharmacokinet
studi
administr
yu
ping
feng
san
rat
differ
dose
gkg
result
calibr
curv
linear
rang
ngml
ngml
intraand
interday
precis
rel
standard
deviat
accuraci
rel
recoveri
extract
recoveri
greater
analyt
dosedepend
shown
constitu
drug
concentrationtim
profil
among
activ
ingredi
detect
cimifugin
highest
blood
concentr
ngml
cycloastragenol
longest
retent
time
rat
bodi
h
conclus
analyt
method
select
sensit
precis
accur
reliabl
assay
simultan
determin
cycloastragenol
calycosin
formononetin
gmv
cimifugin
rat
plasma
yu
ping
feng
san
ypf
chines
jade
windscreen
powder
wellknown
formul
use
tradit
chines
medicin
tcm
consist
weight
combin
radix
saposhnikovia
saposhnikovia
divaricata
turcz
schischk
apiacea
fangfeng
chines
radix
astragali
bge
var
mongholicu
fisch
hsiao
astragalu
membranaceu
fisch
bge
fabacea
huangqi
chines
rhizoma
atractylodi
macrocephala
atractylod
macrocephala
koidz
composita
baizhu
chines
state
pharmacopoeia
committe
ypf
use
treatment
respiratori
diseas
repeat
respiratori
tract
infect
nosocomi
pneumonia
senil
chronic
bronchiti
perenni
allerg
rhiniti
huang
et
al
li
et
al
wang
et
al
yan
et
al
safe
effect
formul
also
reliev
idiopath
sweat
augment
appetit
endstag
cancer
patient
chiu
et
al
use
prevent
viral
infect
includ
sever
acut
respiratori
syndrom
lau
et
al
poon
et
al
report
immunoregulatori
benefici
effect
allerg
rhiniti
asthma
dermat
model
fang
et
al
makino
et
al
makino
et
al
nakatsukasa
et
al
phytochem
serum
pharmacochem
analys
found
ypf
contain
isoflavon
radix
astragali
chromon
radix
saposhnikovia
major
constitu
huang
et
al
zhao
et
al
zheng
et
al
radix
astragali
astragalosid
identifi
potenti
bioactiv
compound
via
intestin
absorpt
cell
extract
studi
xu
et
al
zhang
et
al
furthermor
numer
pharmacolog
studi
shown
antiinflammatori
antivir
antioxid
activ
constitu
astragalosid
astragalosid
iv
primoglucosylcimifugin
wang
et
al
xue
et
al
yin
et
al
yu
et
al
zhang
et
al
zhang
et
al
glycosid
fig
may
explain
effect
ypf
recent
year
pharmacokinet
studi
tradit
chines
medicin
receiv
attent
drug
formul
research
hao
et
al
li
et
al
liu
song
qian
reflect
pharmacokinet
profil
accept
poor
bioavail
low
serum
concentr
short
retent
time
indic
drug
effect
howev
accord
preliminari
experi
relat
literatur
trace
astragalosid
iv
primoglucosylcimifugin
rat
plasma
li
et
al
wen
et
al
ye
et
al
zhang
et
al
cycloastragenol
formononetin
calycosin
cimifugin
metabol
glycosid
vivo
chen
et
al
li
et
al
yung
et
al
aglycon
fig
shown
higher
biolog
activ
glycosid
counterpart
exampl
cycloastragenol
common
aglycon
astragalosid
identifi
telomeras
activ
use
improv
prolif
respons
lymphocyt
hivinfect
patient
fauc
et
al
yung
et
al
calycosin
one
metabolit
exhibit
potent
antioxid
antivir
activ
parent
form
metabolit
chen
et
al
yu
et
al
method
determin
presenc
glycosid
ypf
biolog
sampl
util
highperform
liquid
chromatographi
ultraviolet
hplcuv
huang
et
al
yang
et
al
ye
et
al
hplcmass
spectrometri
ms
dai
et
al
wen
et
al
hplctandem
ms
msm
zhang
et
al
unfortun
report
pharmacokinet
bioactiv
metabolit
human
bodi
li
et
al
exampl
knowledg
report
analysi
cycloastragenol
vivo
therefor
import
develop
method
quantit
analysi
bioactiv
metabolit
pharmacokinet
properti
studi
take
advantag
solidphas
extract
spe
develop
valid
rapid
sensit
method
use
spe
liquid
chromatographi
lc
ms
simultan
quantif
cycloastragenol
formononetin
calycosin
gmv
cimifugin
rat
plasma
also
appli
method
perform
pharmacokinet
studi
ypf
decoct
administ
oral
differ
concentr
cycloastragenol
formononetin
calycosin
gmv
cimifugin
purchas
zelang
pharmaceut
nanj
china
radix
saposhnikovia
radix
astragali
radix
atractylodi
macrocephala
purchas
tongrentang
chines
medicinesinc
beij
china
may
identifi
professor
zhongm
zhou
institut
chines
materia
medica
china
academi
chines
medic
scienc
voucher
specimen
deposit
institut
chines
materia
medica
china
academi
chines
medic
scienc
methanol
hplc
grade
fisher
usa
trichloroacet
acid
purchas
sinopharm
chemic
reagent
china
beij
china
deioniz
water
prepar
milliq
system
millipor
usa
chemic
analyt
grade
spe
cartridg
mg
purchas
dikma
technolog
beij
china
hplcm
system
consist
surveyor
hplc
system
agil
usa
singl
quadrupol
mass
spectromet
agil
usa
equip
electrospray
ioniz
sourc
data
acquisit
analysi
perform
lcmsd
chemstat
softwar
agil
usa
chromatograph
separ
conduct
zorbax
column
id
mm
mm
agil
usa
oven
temperatur
mobil
phase
methanolwat
gradient
elut
produc
start
vv
chang
vv
min
elut
gradual
vv
reach
min
maintain
min
final
ratio
vv
achiev
min
flow
rate
mlmin
inject
volum
ml
mass
spectromet
oper
neg
mode
formononetin
calycosin
posit
mode
cycloastragenol
gmv
cimifugin
quantif
obtain
use
select
ion
monitor
mode
multipl
channel
cycloastragenol
mz
fig
ms
paramet
follow
flow
rate
dri
ga
nitrogen
lmin
nebul
pressur
psig
dri
ga
temperatur
nitrogen
capillari
voltag
v
posit
neg
mode
fragmentor
voltag
ev
gain
set
ms
oper
condit
automat
optim
infus
standard
solut
constitu
electrospray
ioniz
sourc
via
syring
pump
crude
radix
saposhnikovia
radix
astragali
radix
atractylodi
macrocephala
weigh
portion
thoroughli
soak
water
min
first
decoct
water
wv
ad
crude
drug
mixtur
boil
h
decoct
filter
continu
decoct
prepar
water
wv
ad
crude
drug
residu
boil
h
filtrat
decoct
combin
previou
one
concentr
make
two
differ
concentr
gml
crude
drugsdecoct
hplcm
analysi
show
percentag
formononetin
calycosin
gmv
cimifugin
decoct
mgg
respect
stock
solut
cycloastragenol
formononetin
calycosin
gmv
cimifugin
prepar
methanol
calibr
sampl
prepar
spike
blank
plasma
sampl
obtain
final
concentr
ngml
cycloastragenol
formononetin
calycosin
gmv
ngml
cimifugin
qualiti
control
sampl
contain
ngml
cycloastragenol
formononetin
calycosin
gmv
ngml
cimifugin
prepar
manner
stock
solut
store
calibr
qualiti
control
sampl
prepar
need
plasma
sampl
remov
storag
thaw
water
bath
ambient
condit
one
millilit
homogen
plasma
sampl
transfer
microcentrifug
tube
ml
trichloroacet
acid
ad
precipit
protein
vortex
min
centrifug
rpm
min
supernat
load
onto
precondit
spe
cartridg
ie
precondit
ml
methanol
follow
ml
purifi
water
cartridg
rins
twice
ml
water
centrifug
rpm
min
get
rid
residu
water
spe
cartridg
compound
elut
ml
methanol
twice
methanol
fraction
collect
evapor
stream
nitrogen
water
bath
dri
residu
reconstitut
ml
methanolwat
vv
centrifug
rpm
min
ml
supernat
directli
inject
hplcm
system
analysi
fig
method
valid
specif
linear
sensit
specif
method
assess
compar
lowest
concentr
calibr
curv
blank
rat
plasma
undergon
pretreat
analysi
calibr
curv
gener
plot
peak
area
yaxi
plasma
concentr
cycloastragenol
formononetin
calycosin
gmv
cimifugin
xaxi
lower
limit
quantif
lower
limit
determin
defin
final
concentr
produc
signaltonois
ratio
respect
upper
limit
quantif
taken
vivo
peak
concentr
extract
recoveri
matrix
effect
precis
accuraci
stabil
extract
recoveri
determin
use
qualiti
control
plasma
sampl
compar
peak
area
obtain
plasma
sampl
spike
extract
plasma
sampl
spike
extract
matrix
effect
evalu
compar
absolut
peak
area
postextract
control
plasma
spike
known
amount
drug
area
obtain
direct
inject
neat
standard
sampl
equival
concentr
valid
precis
accuraci
carri
qualiti
control
sampl
n
day
intraday
three
consecut
valid
day
interday
intraday
interday
precis
result
base
rel
standard
deviat
whilst
rel
recoveri
rr
calcul
evalu
accuraci
evalu
freez
thaw
stabil
carri
subject
qualiti
control
plasma
sampl
two
freez
andthaw
water
bath
room
temperatur
cycl
roomtemperatur
stabil
evalu
leav
qualiti
control
plasma
sampl
ambient
condit
h
postprepar
stabil
test
keep
sampl
autosampl
condit
h
studi
rat
perform
accord
protocol
requir
anim
care
use
committe
china
academi
chines
medic
scienc
fortyf
male
wistar
rat
week
old
weigh
g
purchas
institut
experiment
anim
academi
militari
medic
scienc
beij
china
rat
randomli
equal
divid
three
treatment
group
fast
overnight
h
prior
oral
administr
low
gkg
bodi
weight
gml
moder
gkg
bodi
weight
gml
high
gkg
bodi
weight
gml
dose
ypf
decoct
blood
sampl
collect
heparin
tube
retroorbit
plexu
punctur
h
oral
dose
kinet
studi
carri
data
least
rat
record
time
point
centrifug
rpm
min
plasma
sampl
store
use
analysi
pharmacokinet
paramet
process
noncompartment
analysi
use
winnonlin
softwar
pharsight
corpor
usa
fig
therefor
ion
select
quantif
use
select
ion
monitor
mode
multipl
channel
fig
gradient
elut
employ
reduc
retent
time
avoid
excess
broaden
peak
develop
chromatograph
condit
retent
time
approxim
min
cycloastragenol
min
formononetin
min
calycosin
min
gmv
min
cimifugin
proelut
tm
spe
cartridg
use
prepar
plasma
sampl
absorpt
capac
nonpolar
compound
also
polar
compound
trichloroacet
acid
use
precipit
protein
dilut
plasma
avoid
block
spe
cartridg
polysaccharid
phospholipid
protein
interf
compound
remov
deioniz
water
reduc
matrix
effect
sampl
improv
sensit
constitu
methanolwat
use
reconstitut
dri
residu
produc
better
peak
summari
method
sampl
prepar
achiev
satisfactori
result
simultan
five
constitu
base
result
trial
test
respect
lower
limit
determin
cycloastragenol
formononetin
calycosin
gmv
cimifugin
set
ngml
lower
limit
quantif
ngml
upper
limit
quantif
ngml
tabl
standard
curv
exhibit
good
linear
select
rang
squar
correl
coeffici
r
cycloastragenol
formononetin
calycosin
gmv
cimifugin
respect
extract
recoveri
determin
analyt
three
concentr
rel
standard
deviat
valu
matrix
effect
rang
rel
standard
deviat
valu
tabl
precis
rel
standard
deviat
valu
intraday
interday
rang
qualiti
control
sampl
accuraci
ie
rel
recoveri
rr
rang
tabl
stabil
result
show
analyt
stabl
plasma
sampl
h
room
temperatur
rr
h
autosampl
condit
prepar
rr
two
freezethaw
cycl
rr
except
calycosin
lowest
level
tabl
thu
subject
sampl
repeat
freezethaw
cycl
avoid
valid
method
describ
herein
success
use
quantifi
five
constitu
ypf
plasma
sampl
oral
administr
ypf
decoct
three
dose
ypf
welltoler
subject
appar
dose
time
depend
toxic
effect
pharmacokinet
paramet
termin
halflif
hl
lz
maximum
concentr
plasma
c
max
area
plasma
concentrationtim
curv
auc
dose
time
extrapol
infin
auc
show
trend
dosedepend
toward
detect
constitu
cycloastragenol
calycosin
gmv
cimifugin
ypf
base
dose
administ
oral
gkg
fig
tabl
formononetin
calycosin
gmv
rapidli
absorb
achiev
c
max
less
min
cycloastragenol
detect
h
plasma
time
c
max
ie
max
around
h
long
mean
resid
time
mrt
h
specul
astragalosid
hydrolyz
cycloastragenol
intestin
stomach
cycloastragenol
absorb
circul
unknown
peak
min
found
select
ion
monitor
channel
one
minut
cycloastragenol
posit
display
similar
pharmacokinet
behavior
cycloastragenol
unknown
peak
identifi
studi
cimifugin
show
multipl
absorpt
peak
among
detect
constitu
concentr
plasma
particularli
high
fig
might
ypf
contain
free
cimifugin
well
precursor
sinc
constitu
especi
cycloastragenol
cimifugin
show
dosedepend
pharmacokinet
profil
result
provid
help
understand
therapeut
process
ypf
howev
show
obviou
dosedepend
formononetin
approv
dosag
rang
administr
larger
rang
dose
warrant
studi
previous
shown
astragalosid
radix
astragali
low
permeabl
vitro
poor
bioavail
vivo
gu
et
al
wen
et
al
howev
aglycon
cycloastragenol
absorb
intestin
epithelium
effici
similar
primoglucosylcimifugin
aglycon
cimifugin
xue
et
al
zhao
et
al
report
chang
telomer
length
relev
immun
function
weng
cycloastragenol
upregul
telomeras
activ
fauc
et
al
yung
et
al
furthermor
cimifugin
inhibit
nitric
oxid
product
contribut
analges
efficaci
radix
saposhnikovia
okuyama
et
al
wang
et
al
taken
togeth
cycloastragenol
cimifugin
demonstr
good
pharmacokinet
behavior
vivo
therefor
cycloastragenol
cimifugin
may
relat
effect
ypf
diseas
respiratori
immun
system
moreov
two
metabolit
may
valuabl
immunoregulatori
antiinflammatori
agent
howev
studi
requir
confirm
associ
cycloastragenol
cimifugin
ypf
pharmacolog
effect
bioactiv
metabolit
could
potenti
drug
present
work
spehplcm
method
simultan
quantif
plasma
concentr
five
constitu
ypf
develop
valid
demonstr
method
select
sensit
precis
accur
reliabl
simultan
determin
cycloastragenol
calycosin
formononetin
gmv
cimifugin
rat
plasma
sampl
addit
pharmacokinet
studi
ypf
appli
differ
dose
